ERNAW
Ernexa Therapeutics Inc.
NASDAQ · Financial Services · Asset Management · US
$0.02
−15.02%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +61.7%
- EBIT
- +40.5%
- Net income
- +68.4%
- EPS
- -42.7%
- Free cash flow
- +56.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026